Milla Maria Koistinaho
Fundador en Aranda Pharma Oy .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Tommi Juha Äijälä | M | - |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014.
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | 10 años |
Pekka Ilmari Simula | M | 50 |
Suomen Bioteollisuus ry
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland.
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | 8 años |
Anders Dalby | M | - |
Teitur Trophics ApS
Teitur Trophics ApS BiotechnologyHealth Technology Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation. | - |
Simon Mølgaard | M | - |
Teitur Trophics ApS
Teitur Trophics ApS BiotechnologyHealth Technology Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation. | - |
Ole Kaasbøll | M | - |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | 4 años |
Hannu Jungman | M | - |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland.
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | 8 años |
Mikko Rautiainen | M | - |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014.
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | 9 años |
Anu Muona | M | - |
Aranda Pharma Oy
Aranda Pharma Oy BiotechnologyHealth Technology Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland. | 9 años |
Petri Tapani Kalliokoski | M | 49 |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | 5 años |
Georg Beiske | M | - |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | - |
Wilhelm Valdemar Lindholm | M | - |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland.
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | 9 años |
Janne Juhani Juhola | M | - |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland.
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | 8 años |
Sara kangaspeska | F | - |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014.
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | 2 años |
Petri Erkki Laine | M | - |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | 8 años |
Mathias Kaas Ollendorff | M | - |
Teitur Trophics ApS
Teitur Trophics ApS BiotechnologyHealth Technology Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation. | - |
Oscar Rautiainen | M | - |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | - |
Päivi Marianne Ihme | F | - |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | 8 años |
Matthew Vaughan | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 8 años |
Heikki Oksala | M | - |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | - |
Paul Anthony Porter | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 7 años |
Tuomas Rekonen | M | - |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | 5 años |
Myron Seto | M | - |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | 6 años |
Mika Ahti Johannes Palsinajärvi | M | - |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | 7 años |
Marko Kuisma | M | - |
Innovestor Ventures Oy
Innovestor Ventures Oy Investment ManagersFinance Innovestor Ventures Oy is a venture capital firm, a subsidiary of Innovestor Oy founded in 2014. The firm is headquartered in Helsinki, Finland. | 2 años |
Björn Ingemar Odlander | M | 66 |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | - |
Kaija Ilona Teräkivi | F | - |
Innovestor Oy
Innovestor Oy Investment ManagersFinance Innovestor Oy is a venture and growth equity firm headquartered in Helsinki, Finland. The firm was founded by Tommi Äijälä and Antti Parviainen in 2014. | 9 años |
Jari Eerik Koistinaho | M | - |
Aranda Pharma Oy
Aranda Pharma Oy BiotechnologyHealth Technology Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland. | 9 años |
Jørgen Søberg Petersen | M | - |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | - |
Juha Tatu Henrik Holopainen | M | 65 |
Aranda Pharma Oy
Aranda Pharma Oy BiotechnologyHealth Technology Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland. | - |
Anthony Giovinazzo | M | 67 |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 2 años |
Aki Pellervo Prihti | M | 53 |
Aranda Pharma Oy
Aranda Pharma Oy BiotechnologyHealth Technology Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland. | - |
Heikki Matti Kalervo Hautsalo | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 8 años |
Elias Papatheodorou | M | 55 |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | - |
David Hinton | M | 60 |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 3 años |
Kanyin E. Zhang | M | - |
Aranda Pharma Oy
Aranda Pharma Oy BiotechnologyHealth Technology Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland. | - |
Paul Grant Higham | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 4 años |
Taina Tellervo Kyllönen | F | 57 |
Helsinki Innovation Services Ltd.
Helsinki Innovation Services Ltd. Miscellaneous Commercial ServicesCommercial Services Part of University of Helsinki, Helsinki Innovation Services Ltd. is a company that provides business and innovation-related consulting services. The company is based in Helsinki, Finland. | 4 años |
Charles H. Large | M | - |
Teitur Trophics ApS
Teitur Trophics ApS BiotechnologyHealth Technology Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation. | - |
Mai-Britt Zocca | M | 56 |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 4 años |
Jonas Karl Hansson | M | 50 |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | - |
João Ribas | M | - |
Tribune Therapeutics AB
Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | - |
Gundars Goldsteins | M | - |
Aranda Pharma Oy
Aranda Pharma Oy BiotechnologyHealth Technology Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland. | 9 años |
Gregory Jones | M | - |
Teitur Trophics ApS
Teitur Trophics ApS BiotechnologyHealth Technology Teitur Trophics ApS develops novel treatments. The company is based in Aarhus, Denmark. The Danish company was founded by Simon Mølgaard, Mathias Kaas Ollendorff, Anders Dalby, Simon Glerup. Simon Mølgaard has been the CEO since incorporation. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Timo Ilari Veromaa | M | 64 |
Suomen Bioteollisuus ry
| 6 años |
Antti Vuolanto | M | - |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | 1 años |
Liisa Hurme | M | 57 |
Suomen Bioteollisuus ry
| 6 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Finlandia | 34 | 73.91% |
Suecia | 7 | 15.22% |
Dinamarca | 5 | 10.87% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Milla Maria Koistinaho
- Red Personal